| [1] |
Caers J, Paiva B, Zamagni E , et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel[J]. J Hematol Oncol, 2018,11(1):10. DOI: 10.1186/s13045-017-0549-1.
doi: 10.1186/s13045-017-0549-1
|
| [2] |
Hughes M, Doig A, Soutar R . Solitary plasmacytoma and multiple myeloma: adhesion molecule and chemokine receptor expression patterns[J]. Br J Haematol, 2007,137(5):486-487. DOI: 10.1111/j.1365-2141.2007.06599.x.
doi: 10.1111/bjh.2007.137.issue-5
|
| [3] |
Chen LP, Sun TH, Hsieh PP , et al. Diagnostic pitfalls of nonsecretory myeloma manifesting as multiple foci of periosseous plasmacytomas[J]. J Chin Med Assoc, 2011,74(10):464-468. DOI: 10.1016/j.jcma.2011.08.018.
doi: 10.1016/j.jcma.2011.08.018
|
| [4] |
Tsang RW, Campbell BA, Goda JS , et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group[J]. Int J Radiat Oncol Biol Phys, 2018,101(4):794-808. DOI: 10.1016/j.ijrobp.2018.05.009.
doi: 10.1016/j.ijrobp.2018.05.009
|
| [5] |
Mignot F, Schernberg A, Arsène Henry A , et al. Solitary plasmacytoma: lenalidomide-dexamethasone combined with radiation therapy: clinical outcomes[J]. Int J Radiat Oncol Biol Phys, 2020,106(3):589-596. DOI: 10.1016/j.ijrobp.2019.10.043.
doi: 10.1016/j.ijrobp.2019.10.043
|
| [6] |
Katodritou E, Kastritis E, Gatt M , et al. Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the novel therapeutic era: a study of the Greco-Israeli Collaborative Myeloma Working Group[J]. Am J Hematol, 2020, In press. DOI: 10.1002/ajh.25755.
|
| [7] |
Goranova Marinova V, Yaneva M, Deneva T , et al. Multiple myeloma with advanced bone disease and low tumor burden-different clinical presentation but similar outcome after bortezomib-based therapy and radiotherapy[J]. Acta Clin Croat, 2017,56(2):262-268. DOI: 10.20471/acc.2017.56.02.09.
|
